Format

Send to

Choose Destination
Sci Signal. 2016 Aug 9;9(440):tc2. doi: 10.1126/scisignal.aad9777.

Response to Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML".

Author information

1
Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
2
Proteomics and Biological Resources, Genentech Research and Early Development, South San Francisco, CA 92056, USA.
3
Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. gsalvesen@sbpdiscovery.org.

Abstract

Arsenic trioxide chemotherapy cures acute promyelocytic leukemia by inducing the ubiquitylation of an oncogenic fusion protein containing promyelocytic leukemia protein (PML) subsequent to modification of PML by SUMO1 and SUMO2. We proposed that the SUMO switch at Lys(65) of PML enhanced subsequent SUMO2 conjugation to Lys(160) and consequent RNF4-dependent ubiquitylation of PML. Ferhi et al note differences between their experimental system and ours regarding the outcome and mechanisms of SUMO-dependent PML signaling. When confronted by apparently contradictory data, it is appropriate to drill down to where the differences could lie.

PMID:
27507652
DOI:
10.1126/scisignal.aad9777
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center